Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Artisan Global Discovery. This analysis is provided for institutional research purposes only and is not investment advice.
"Despite lagging its benchmark in 2025, the fund generated strong absolute gains and is shifting capital into robust biotech launches and under-the-radar AI infrastructure plays."
In Q4 and full-year 2025, the Artisan Global Discovery Fund generated strong absolute returns but underperformed its benchmark, the MSCI All Country World Small Mid Index. Underperformance was primarily driven by stock selection in Consumer Discretionary and Communication Services in Q4, and IT and Financials for the full year. Conversely, Healthcare (including Argenx, Insmed, and Veracyte) was the strongest absolute contributor. The fund initiated new positions in Texas Roadhouse, TopBuild, and SailPoint, and expanded several existing software and energy tech holdings. It also exited campaigns in Nemetschek and Samsara, while trimming several strong performers (including Coherent, Babcock, iRhythm, and MACOM) on valuation discipline.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Despite lagging its benchmark in 2025, the fund generated strong absolute gains and is shifting capital into robust biotech launches and under-the-radar AI infrastructure plays....
Growth Outlook
Market outlook remains above average conviction: Despite lagging its benchmark in 2025, the fund generated strong absolute gains and is shifting capital into robust biotech launches and under-the-radar AI infrastructure plays....
Risk Appetite
Risk appetite posture is above average conviction: Despite lagging its benchmark in 2025, the fund generated strong absolute gains and is shifting capital into robust biotech launches and under-the-radar AI infrastructure plays....
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Despite lagging its benchmark in 2025, the fund generated strong absolute gains and is shifting capital into robust biotech launches and under-the-radar AI infrastructure plays....
Forward Guidance
Forward guidance signal: Despite lagging its benchmark in 2025, the fund generated strong absolute gains and is shifting capital into robust biotech launches and under-the-radar AI infrastructure plays....
Language Signal
Tone analysis indicates above average conviction language: Despite lagging its benchmark in 2025, the fund generated strong absolute gains and is shifting capital into robust biotech launches and under-the-radar AI infrastructure plays....
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Despite lagging its benchmark in 2025, the fund generated strong absolute gains and is shifting capital into robust biotech launches and under-the-radar AI infrastructure plays....
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. Despite lagging its benchmark in 2025, the fund generated strong absolute gains and is shifting capital into robust biotech launches and under-the-radar AI infrastructure plays....
Time Horizon
Investment time horizon reflects a high conviction orientation. Despite lagging its benchmark in 2025, the fund generated strong absolute gains and is shifting capital into robust biotech launches and under-the-radar AI infrastructure plays....
